%0 Journal Article %1 Snyder.2005 %A Snyder, L. C. %A Astsaturov, I. %A Weiner, L. M. %D 2005 %J Clin.Colorectal Cancer %K & Administration Amplification Antibodies Approval Binding Colorectal Drug Epidermal Exanthema Factor Food Gene Growth Humans IgG Ligands Medical Molecular Monoclonal Neoplasms Oncology Phosphorylation Prognosis Receptor Receptors Signal Sites States Transduction Tyrosine United Weight and antagonists biosynthesis cells chemically drug induced inhibitors pharmacology physiology physiopathology response therapeutic therapy use %P S71-S80 %T Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer %U PM:16336752 %V 5 Suppl 2 %X The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancers. As more is learned about the molecular details of EGFR signaling, antibodies can be designed to interfere with specific domains of the EGFR molecule. In this review, we analyze preclinical and current clinical data on EGFR-targeting molecules and their potential role in the treatment of colorectal cancer. Cetuximab binds to domain III of EGFR and hinders ligand binding. It is now approved by the US Food and Drug Administration for metastatic colorectal cancer treatment. Panitumumab is another widely studied anti-EGFR antibody with similar properties. Bispecific antibodies are modified immunoglobulin molecules containing 2 different binding specificities. These antibodies can redirect the immune response against tumor cells by tethering effector cells such as CD3e-expressing T cells or CD16-expressing natural killer cells and granulocytes to the surface of ca

@article{Snyder.2005, abstract = {The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancers. As more is learned about the molecular details of EGFR signaling, antibodies can be designed to interfere with specific domains of the EGFR molecule. In this review, we analyze preclinical and current clinical data on EGFR-targeting molecules and their potential role in the treatment of colorectal cancer. Cetuximab binds to domain III of EGFR and hinders ligand binding. It is now approved by the US Food and Drug Administration for metastatic colorectal cancer treatment. Panitumumab is another widely studied anti-EGFR antibody with similar properties. Bispecific antibodies are modified immunoglobulin molecules containing 2 different binding specificities. These antibodies can redirect the immune response against tumor cells by tethering effector cells such as CD3e-expressing T cells or CD16-expressing natural killer cells and granulocytes to the surface of ca}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Snyder, L. C. and Astsaturov, I. and Weiner, L. M.}, biburl = {https://www.bibsonomy.org/bibtex/283184e47b56666975dfde7ac6bd5c046/kanefendt}, interhash = {4d569af965b4455f2e7df7a44a3c9cb5}, intrahash = {83184e47b56666975dfde7ac6bd5c046}, journal = {Clin.Colorectal Cancer}, keywords = {& Administration Amplification Antibodies Approval Binding Colorectal Drug Epidermal Exanthema Factor Food Gene Growth Humans IgG Ligands Medical Molecular Monoclonal Neoplasms Oncology Phosphorylation Prognosis Receptor Receptors Signal Sites States Transduction Tyrosine United Weight and antagonists biosynthesis cells chemically drug induced inhibitors pharmacology physiology physiopathology response therapeutic therapy use}, pages = {S71-S80}, timestamp = {2010-02-05T11:28:43.000+0100}, title = {Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer}, url = {PM:16336752}, volume = {5 Suppl 2}, year = 2005 }